Beránek Martin, Sirák Igor, Vošmik Milan, Petera Jiří, Drastíková Monika, Palička Vladimír
Department of Biochemical Sciences, Charles University, Faculty of Pharmacy in Hradec Králové, Czech Republic.
Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Charles University, Faculty of Medicine in Hradec Králové, Czech Republic.
Acta Medica (Hradec Kralove). 2016;59(2):54-8. doi: 10.14712/18059694.2016.54.
The aims of the study were: i) to compare circulating tumor DNA (ctDNA) yields obtained by different manual extraction procedures, ii) to evaluate the addition of various carrier molecules into the plasma to improve ctDNA extraction recovery, and iii) to use next generation sequencing (NGS) technology to analyze KRAS, BRAF, and NRAS somatic mutations in ctDNA from patients with metastatic colorectal cancer. Venous blood was obtained from patients who suffered from metastatic colorectal carcinoma. For plasma ctDNA extraction, the following carriers were tested: carrier RNA, polyadenylic acid, glycogen, linear acrylamide, yeast tRNA, salmon sperm DNA, and herring sperm DNA. Each extract was characterized by quantitative real-time PCR and next generation sequencing. The addition of polyadenylic acid had a significant positive effect on the amount of ctDNA eluted. The sequencing data revealed five cases of ctDNA mutated in KRAS and one patient with a BRAF mutation. An agreement of 86% was found between tumor tissues and ctDNA. Testing somatic mutations in ctDNA seems to be a promising tool to monitor dynamically changing genotypes of tumor cells circulating in the body. The optimized process of ctDNA extraction should help to obtain more reliable sequencing data in patients with metastatic colorectal cancer.
i)比较不同手工提取方法获得的循环肿瘤DNA(ctDNA)产量;ii)评估向血浆中添加各种载体分子以提高ctDNA提取回收率;iii)使用下一代测序(NGS)技术分析转移性结直肠癌患者ctDNA中的KRAS、BRAF和NRAS体细胞突变。从患有转移性结直肠癌的患者中采集静脉血。对于血浆ctDNA提取,测试了以下载体:载体RNA、聚腺苷酸、糖原、线性丙烯酰胺、酵母tRNA、鲑鱼精DNA和鲱鱼精DNA。每种提取物通过定量实时PCR和下一代测序进行表征。添加聚腺苷酸对洗脱的ctDNA量有显著的积极影响。测序数据显示5例ctDNA发生KRAS突变,1例患者发生BRAF突变。肿瘤组织与ctDNA之间的一致性为86%。检测ctDNA中的体细胞突变似乎是一种有前景的工具,可用于动态监测体内循环肿瘤细胞不断变化的基因型。优化的ctDNA提取过程应有助于在转移性结直肠癌患者中获得更可靠的测序数据。